Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus KERLEDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus KERLEDEX.
FLOVENT DISKUS 250 vs KERLEDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines, reduction of eosinophil recruitment, and suppression of airway hyperresponsiveness.
Kerledex is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
250 mcg inhaled orally via DISKUS twice daily (500 mcg total daily dose).
Intravenous: 500 mg every 6 hours; Oral: 250 mg every 8 hours.
None Documented
None Documented
Approximately 10-12 hours (terminal elimination half-life in asthmatics).
Terminal half-life 12 hours (range 10–14) in normal renal function; extended to 30–50 hours in severe renal impairment (CrCl <30 mL/min); 6–8 hours in hepatic cirrhosis.
Renal (approximately 5% as unchanged drug); fecal (majority as metabolites and unabsorbed drug).
Renal: 70% unchanged; fecal/biliary: 20% as metabolites; 10% as minor metabolites. Total renal clearance 180 mL/min, active tubular secretion accounts for 60% of renal elimination.
Category C
Category C
Corticosteroid
Corticosteroid/Antibiotic Combination